Crossmark

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

Crossref DOI link: https://doi.org/10.1007/s40121-022-00607-x

Published Online: 2022-03-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Joe http://orcid.org/0000-0002-8158-3003
Naik, Jaesh

Massello, Matthew

Ralph, Lewis

Dillon, Ryan James
License Information

Text and Data Mining valid from 2022-03-25

Version of Record valid from 2022-03-25
More Information

Article History

Received: 8 November 2021

Accepted: 9 February 2022

First Online: 25 March 2022

Change Date: 24 June 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40121-022-00660-6

Updates are available Correction dated 2022-06-24

Click to view Correction: https://doi.org/10.1007/s40121-022-00660-6